Short answer
Prestige Consumer Healthcare Inc. (PBH) filed its fiscal 2025 10-K annual report with the SEC on May 9, 2025. It reported revenue of $1.1B (+1.1% year over year) and net income of $215M.
- Top risk flagged: Legal risk from regulatory compliance with FASB ASC 280 and ASC 718 on goodwill and stock-based compensation valuation affecting reported assets and expenses
FY2025 key financial metrics · XBRL
- Revenue
- $1.1B
- +1.1% YoY
- Net income
- $215M
- +2.5% YoY
- Operating margin
- 29.6%
- −0.8 pp YoY
- Gross margin
- 55.8%
- +0.3 pp YoY
- EPS (diluted)
- $4.29
- +2.9% YoY
- ROE
- 11.7%
- −1.0 pp YoY
- Operating cash flow
- $252M
- +1.0% YoY
Source: XBRL data from the Prestige Consumer Healthcare Inc. (PBH) FY2025 10-K on SEC EDGAR. USD.
Prestige Consumer Healthcare Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Consumer healthcare products competing on brand recognition, quality, price, and availability through retail and e-commerce channels
- Largest customers Walmart and Amazon accounted for 19% and 14% of revenues respectively, with top ten customers expected to increase share
- 16% of 2025 revenues from international markets, reliance on brokers/distributors with risks of political instability, currency controls, and tariffs
- Manufacturing facility in Lynchburg, VA produces ~15% of revenues, supported by third-party distribution in Clayton, IN, exposed to supply disruptions
- Increased regulatory scrutiny with FDA inspections resuming post-COVID, impacting production timelines and supply chain stability
Management Discussion & Analysis
- Net cash from operations $251.5M, up $2.6M YoY; investing cash use $17.5M, down $2.7M; financing cash outflow $182.1M, down $58.9M
- No reported revenue or profit/margin figures in section to analyze
- Best cash flow segment: operating activities $251.5M; worst: financing activities outflow $182.1M
- Capital allocation: $26.5M increased stock repurchases, capital expenditures $17.5M, full repayment of 2012 Term Loan in fiscal 2025
- Management expects liquidity from operations and credit facilities adequate for next 12 months; inflation and supply chain risks noted as key uncertainties
Risk Factors
- Legal risk from regulatory compliance with FASB ASC 280 and ASC 718 on goodwill and stock-based compensation valuation affecting reported assets and expenses
- Macroeconomic threat from inflation, tariffs, and global supply chain disruptions causing shortages and price increases, notably impacting eye care product availability
- Supply chain vulnerability due to third-party manufacturers struggling to meet demand, leading to product shortages and negative sales impact
- Market disruption risk from potential technological advances and changing consumer preferences affecting brand valuations and triggering impairment charges
- Financial risk of goodwill and intangible asset impairments; $6.6M impairment in FY2025 linked to non-strategic brands reflecting shifting sales priorities
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.